Perfusion Imaging Score to Predict Delayed Cerebral Ischemia
Launched by STANFORD UNIVERSITY · Jun 12, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to predict a serious complication called delayed cerebral ischemia (DCI) that can happen after a type of brain bleed known as aneurysmal subarachnoid hemorrhage (aSAH). This complication affects many patients and can lead to brain damage or disability if not caught early. The study will look at a special type of brain imaging called perfusion imaging to see if it can help doctors identify who is at risk for DCI sooner, which may help improve recovery and brain function.
Adults over 18 who have been diagnosed with aSAH may be eligible to join, unless they have certain conditions like severe kidney disease, pregnancy, or allergies to the imaging dye, or if they have difficulties that would prevent them from completing memory and thinking tests. Participants will undergo brain scans and assessments to help researchers understand how well perfusion imaging predicts DCI and affects thinking and neurological health. This study has not started recruiting yet, but it aims to improve care and outcomes for people recovering from this type of brain bleed.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \>18 years with a diagnosis of aSAH
- Exclusion Criteria:
- • chronic kidney disease stage IV
- • pregnancy
- • allergy to iodine that precludes CTP
- • subjects with significant aphasia, blindness, or other factors that limit their participation in the cognitive assessment
About Stanford University
Stanford University is a prestigious academic institution renowned for its cutting-edge research and innovation in healthcare and medicine. As a clinical trial sponsor, Stanford leverages its extensive resources, including a collaborative network of world-class researchers and state-of-the-art facilities, to advance medical knowledge and improve patient care. The university is committed to conducting rigorous, ethical research that adheres to the highest standards of scientific integrity, fostering an environment where groundbreaking discoveries can translate into effective clinical applications. Through its clinical trials, Stanford aims to address critical health challenges and contribute to the development of novel therapies and treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported